ArticleEndocrine connections2026
Management of non-medical androgen use: a position statement by the Society for Endocrinology.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-medical androgen use, commonly involving anabolic-androgenic steroids, represents an increasing public health concern. Non-medical androgen use is associated with significant morbidity and mortality, including cardiovascular disease, erythrocytosis, dyslipidaemia, infertility, sexual dysfunction, psychiatric manifestations and suppression of the hypothalamic-pituitary-gonadal axis. Men with current or previous non-medical androgen use are increasingly presenting to endocrine and reproductive medicine services, often with hypogonadal symptoms, infertility or concerns regarding recovery following cessation. However, both patients and clinicians frequently report mistrust, uncertainty and limited confidence in management approaches. This Society for Endocrinology position statement summarises the currently available evidence relating to non-medical androgen use, associated health consequences, biochemical recovery following cessation and potential management strategies. Current evidence suggests that most men will experience biochemical recovery of the HPG axis within approximately 12 months of androgen cessation, although recovery timelines vary substantially and some individuals may develop persistent hypogonadism. Symptoms such as low mood, fatigue, anxiety and sexual dysfunction may persist despite biochemical recovery and are likely influenced by psychological factors in addition to serum testosterone concentrations. Existing evidence supporting pharmacological interventions, including human chorionic gonadotrophin, selective oestrogen receptor modulators, aromatase inhibitors or testosterone therapy, remains limited and of low quality, with no robust evidence demonstrating improved long-term recovery or symptom outcomes. Clinicians should approach individuals who misuse androgens with compassion, professionalism and a non-judgemental attitude while remaining alert to undisclosed androgen use. Further longitudinal and interventional studies are required to better characterise recovery trajectories, identify predictors of persistent morbidity and inform evidence-based management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.